849217-48-7

Basic information

• Product Name: 1-(4-FLUOROPHENYLCARBAMOYL)CYCLOPROPANECARBOXYLIC ACID
• Synonyms: 1-(4-FLUOROPHENYLCARBAMOYL)CYCLOPROPANECARBOXYLIC ACID;Cyclopropanecarboxylic acid, 1-[[(4-fluorophenyl)aMino]carbonyl]-;1-{[(4-fluorophenyl)aMino]carbonyl}cyclopropanecarboxylic acid;InterMediate of Cabozantinib;FLUOROPHENYLCARBAMOYL)CYCLOPROPANECARBOXYLIC ACID;((4-fluorophenyl)carbamoyl)cyclopropane carboxylic acid;1-(5-FLUOROPHENYLCARBAMOYL)CYCLOPROPANECARBOXYLIC ACID;Intermediate2 of Cabozantinib
• CAS NO: 849217-48-7
• Molecular Formula: C₁₁H₁₀FNO₃
• Molecular Weight: 223.21
• EINECS: 1592732-453-0
• Mol File: 849217-48-7.mol
• Article Data: 57

Chemical Properties

• Melting Point: 173.0 to 177.0 °C
• Boiling Point: 475.2oC at 760 mmHg
• Flash Point: 241.2oC
• Appearance: /
• Density: 1.521
• Vapor Pressure: 7.78E-10mmHg at 25°C
• Refractive Index: 1.651
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 3.48±0.20(Predicted)
• CAS DataBase Reference: 1-(4-FLUOROPHENYLCARBAMOYL)CYCLOPROPANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-FLUOROPHENYLCARBAMOYL)CYCLOPROPANECARBOXYLIC ACID(849217-48-7)
• EPA Substance Registry System: 1-(4-FLUOROPHENYLCARBAMOYL)CYCLOPROPANECARBOXYLIC ACID(849217-48-7)

Safety Data

• Hazardous Substances Data: 849217-48-7(Hazardous Substances Data)

Usage

Description

1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid is a white powdery substance that serves as a valuable research chemical. It is primarily recognized for its role as an intermediate in the synthesis of cabozantinib, a medication with potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid is used as a cabozantinib intermediate for the development of pharmaceuticals. It plays a crucial role in the synthesis of cabozantinib, which is a medication with potential applications in treating various medical conditions, such as cancer. Its contribution to the production of cabozantinib highlights its importance in the pharmaceutical industry.

InChI:InChI=1/C11H10FNO3/c12-7-1-3-8(4-2-7)13-9(14)11(5-6-11)10(15)16/h1-4H,5-6H2,(H,13,14)(H,15,16)

Upstream product

• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 371-40-4 4-fluoroaniline 
• 1245931-90-1 ethyl 1-(4-fluorophenylcarbamoyl)cyclopropanecarboxylate 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 34782-60-0 cyclopropane-1,1-dicarboxylic acid dichloride 
• 372-19-0 meta-fluoroaniline 
• 3697-66-3 1,1-cyclopropanedicarboxylic acid monoethyl ester 
• 1174171-88-0 C₇H₉O₄^(1-)*Na⁽¹⁺⁾ 
• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 
• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 
• 1345847-71-3 methyl 1-((4-fluorophenyl)amidomethyl)cyclopropyl-1-carboxylate 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 

Downstream Products

• 928038-30-6 4-(3-Fluoro-4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl] amino }phenoxy)pyridine-2-carboxamide 
• 849217-58-9 N'-(3-fluoro-4-hydroxyphenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1342835-09-9 tert-butyl 2-(6-(7-(2-fluoro-4-(1-(4-fluorophenylcarbamoyl)cyclopropanecarboxamido)phenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)ethyl(2-methoxyethyl)carbamate 
• 928038-31-7 N-{4-[(2-Aminopyridin-4-yl)oxy]-2-fluorophenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 928038-40-8 N-(4-{[2-Aminopyridin-4-yl)oxy]-2,5-difluorophenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-28-3 (S)-1-[4-(2,5-difluoro-4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-ylcarbamoyl]ethyl acetate 
• 1345848-30-7 (S)-N-(2,5-difluoro-4-((2-(2-hydroxypropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-32-9 N-(2,5-difluoro-4-((2-(2-fluoro-2-methylpropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-77-9 N-[4-(2-chloropyridin-4-yloxy)-2,5-difluorophenyl]-N'-[4-fluorophenyl]cyclopropane-1,1-dicarboxamide 
• 1345847-79-1 N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-81-5 N-(5-chloro-4-(2-chloropyridin-4-yloxy)-2-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-83-7 N-(4-(2-acetamidopyridin-4-yloxy)-5-chloro-2-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-89-3 N-(4-(2-(2-(dimethylamino)acetamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-93-9 N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

Preparation method of broad-spectrum anti-cancer drug kimatinib (by machine translation)

The preparation method is simple, the reaction conditions are mild . the reaction conditions are mild, the intermediate stability is good, the side reaction: is less likely to occur, and the preparation method is very suitable for industrial production: a

Method of Treating Cancer and Bone Cancer Pain

This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in a